OncoSec Medical Inc (ONCSQ)

[guti]

No it does not, which is a good thing because the adverse events are pretty high and that is exactly what the ImmunoPulse platform will try to help out with, along with better results. I thought I had explained that when I wrote:

A growing number of clinical trials and the results already available underline the strong potential of DNA electroporation which combines both safety and efficiency Immunopulse platform is working on dealing with the adverse events while trying to improve on the amount of responders.

Notice that right after, I posted about the combination of Ipilimumab/Pembrolizumab to show that it reduces toxicity in advanced melanoma while producing better results than the Nivolumab/ipilimumab combination.
What if EP IL-12 with Pembrolizumab gets the same or better results and with very low adverse events, possibly due to the fact that the patient will not need to be on the treatment for as long of a time. Electroporation will help Keytruda act directly on the cells and reaction will take place at a faster pace, while protecting the patient from prolonged usage that can damage the body. And IL-12 can help to raise those TIL's and hopefully some of the non-responders can be cured, and better results are obtained.